Spun-out of SBIR firm Hawaii BioTech in 2006, Cardax Pharma - aka Cardax Pharmaceuticals - is a development stage life sciences company organized around proprietary small molecule therapies for those unmet medical needs where oxidative stress and inflammation play important causative roles. These include including dyslipidemia, metabolic disease, arthritis, cardiovascular disease, hepatitis, macular degeneration and others. Offerng an alternative to the condition where most anti-inflammatory drugs can have significant safety and side effect issues that limit their utility, Cardax product offerings - proprietary, synthetic, natural compound derivatives - represent a novel treatment approach that offers robust efficacy combined with exceptional safety, oral bioavailability, and tissue selectivity. The Company also develops consumer health and pharmaceutical technologies: anti-inflammatory dietary supplements and drugs. that include ZanthoSyn, a product to help consumers address their inflammatory health; ZanthoSyn is an astaxanthin dietary supplement distributed by the Company. ZanthoSyn features synthetic astaxanthin; Astaxanthin is an ingredient with anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health and liver health. SInce December 2015, the Company alsohas two other anti-inflammatory programs with application in various markets, including zeaxanthin esters for macular degeneration and hepatic disease, and lycophyll esters for prostate disease.
